1. In Vivo
  2. >>Deal-Making

IN VIVO’s Deals Of The Month: January 2016

 
• By Nancy Dvorin

IN VIVO’s editors pick January's top alliance, financing and M&A deals (free with registration).

Stealthy start-up Receptor Life Sciences Inc. has licensed MannKind Corp.'s Technosphere dry powder delivery platform to develop inhaled formulations of undisclosed Receptor candidates. [See Deal] The companies will work together on clinical development, with MannKind in charge of initial formulation studies and Receptor handling development costs as well as manufacturing and commercialization. MannKind, which is strapped for cash following the demise of its SanofiAfrezza marketing deal, could receive up to $102.25 million in development and commercialization milestones, plus royalties.

Grail Bio raised a $100 million-plus Series A round from Arch Venture Partners, Bill Gates, Bezos Expeditions, Sutter Hill Ventures and Illumina Inc., which is the majority owner of its spin-out. [See Deal] Grail will develop technology to screen asymptomatic patients for cancer through the detection of circulating tumor DNA

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

Dealmaking Quarterly Statistics, Q1 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

Deals In Depth: March 2025

 
• By Maureen Riordan

Eight $1bn+ alliances were penned in March, and five exceeded $2bn.

More from In Vivo

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

Rising Leaders 2025: Flagship’s Jacob Rubens On Building The Next Generation Of Biotech

 
• By David Wild

Rising Leader Jacob Rubens, who has co-founded and led several Flagship companies and is now origination partner, believes aspiring leaders should follow their bliss.